HeartBeam (BEAT)
Market Price (3/30/2026): $1.12 | Market Cap: $40.4 MilSector: Health Care | Industry: Health Care Technology
HeartBeam (BEAT)
Market Price (3/30/2026): $1.12Market Cap: $40.4 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% | Weak multi-year price returns2Y Excs Rtn is -68%, 3Y Excs Rtn is -117% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Digital Health & Telemedicine, and Precision Medicine. Themes include Advanced Diagnostics, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -55% | ||
| High stock price volatilityVol 12M is 149% | ||
| Key risksBEAT key risks include [1] a precarious financial position due to zero revenue and a high cash burn rate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Digital Health & Telemedicine, and Precision Medicine. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -68%, 3Y Excs Rtn is -117% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -55% |
| High stock price volatilityVol 12M is 149% |
| Key risksBEAT key risks include [1] a precarious financial position due to zero revenue and a high cash burn rate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
HeartBeam (BEAT) stock has gained about 50% since 11/30/2025 because of the following key factors:
1. HeartBeam received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment in December 2025. This regulatory approval was a pivotal milestone, enabling the company to advance its commercialization efforts for its cable-free, clinical-grade cardiac monitoring platform.
2. The company initiated a limited commercial launch of its 12-lead ECG device for arrhythmia assessment and secured its first commercial partnership with ClearCardio™. This launch, following the December 2025 FDA clearance, targets the concierge and preventive cardiology market with a projected annual revenue of $500 to $1,000 per patient.
Show more
1. HeartBeam received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment in December 2025. This regulatory approval was a pivotal milestone, enabling the company to advance its commercialization efforts for its cable-free, clinical-grade cardiac monitoring platform.
2. The company initiated a limited commercial launch of its 12-lead ECG device for arrhythmia assessment and secured its first commercial partnership with ClearCardio™. This launch, following the December 2025 FDA clearance, targets the concierge and preventive cardiology market with a projected annual revenue of $500 to $1,000 per patient.
Show more
Stock Movement Drivers
Fundamental Drivers
The 48.1% change in BEAT stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.77 | 1.14 | 48.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 34 | 36 | -4.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| BEAT | 48.1% | |
| Market (SPY) | -5.3% | 19.3% |
| Sector (XLV) | -8.7% | 19.3% |
Fundamental Drivers
The -15.6% change in BEAT stock from 8/31/2025 to 3/29/2026 was primarily driven by a -6.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.35 | 1.14 | -15.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 34 | 36 | -6.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| BEAT | -15.6% | |
| Market (SPY) | 0.6% | 10.7% |
| Sector (XLV) | 5.2% | 2.8% |
Fundamental Drivers
The -43.6% change in BEAT stock from 2/28/2025 to 3/29/2026 was primarily driven by a -25.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.02 | 1.14 | -43.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 27 | 36 | -25.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| BEAT | -43.6% | |
| Market (SPY) | 9.8% | 14.0% |
| Sector (XLV) | -2.1% | 8.4% |
Fundamental Drivers
The -67.1% change in BEAT stock from 2/28/2023 to 3/29/2026 was primarily driven by a -77.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.47 | 1.14 | -67.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 8 | 36 | -77.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| BEAT | -67.1% | |
| Market (SPY) | 69.4% | 18.0% |
| Sector (XLV) | 18.4% | 10.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BEAT Return | -34% | 58% | -52% | -2% | 4% | -55% | -77% |
| Peers Return | 24% | -38% | -16% | -0% | 10% | -17% | -41% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| BEAT Win Rate | 0% | 50% | 50% | 42% | 42% | 33% | |
| Peers Win Rate | 58% | 33% | 44% | 47% | 48% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| BEAT Max Drawdown | -38% | -62% | -77% | -41% | -75% | -55% | |
| Peers Max Drawdown | -7% | -47% | -30% | -31% | -23% | -21% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: OMCL, MDRX, VEEV, SOLV, TEM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | BEAT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -81.0% | -25.4% |
| % Gain to Breakeven | 425.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to OMCL, MDRX, VEEV, SOLV, TEM
In The Past
HeartBeam's stock fell -81.0% during the 2022 Inflation Shock from a high on 12/13/2022. A -81.0% loss requires a 425.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About HeartBeam (BEAT)
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
AI Analysis | Feedback
Here are 1-3 brief analogies for HeartBeam (BEAT):
- It's like **Apple Health** (or Apple Watch's health features) but for doctors to remotely diagnose and manage serious heart conditions.
- Imagine **Teladoc Health** for your heart, specifically using a smart device to continuously monitor and send data to your cardiologist.
- Think of it as a **Fitbit** that provides clinical-grade ECGs directly to doctors for remote heart disease management.
AI Analysis | Feedback
- Credit Card Sized Electrocardiogram (ECG) Machine: A portable device for remote detection and monitoring of cardiac activity outside a healthcare facility.
- Cloud-based Diagnostic Software System: A software platform that processes and analyzes patient data from the ECG machine, providing diagnostic information to physicians.
AI Analysis | Feedback
Major Customers of HeartBeam (BEAT)
HeartBeam, Inc. primarily sells its telemedicine solutions to other companies, specifically healthcare providers and organizations. Due to the company's early stage of commercialization, specific individual "major customers" (i.e., named companies that account for a significant portion of revenue) are not publicly disclosed in their financial filings. However, their commercialization strategy indicates they target the following categories of healthcare entities:
- Cardiology Groups: Medical practices specializing in the diagnosis and treatment of heart conditions.
- Electrophysiology Groups: Specialists focused on the electrical activities of the heart, often dealing with arrhythmias.
- Primary Care Physicians: General practitioners who would use HeartBeam's technology for initial screening, monitoring, and referral of patients with potential cardiac issues.
HeartBeam intends to sell its devices and provide its monitoring services to these healthcare providers, who will then offer the solutions to their patients for remote cardiac monitoring and data collection.
AI Analysis | Feedback
nullAI Analysis | Feedback
Robert P. Eno, Chief Executive OfficerRobert P. Eno joined HeartBeam as President in January 2023 and was appointed Chief Executive Officer in October 2024. He brings over 30 years of experience in the medical technology industry, with a proven track record of developing markets and commercializing disruptive medical technologies. Before HeartBeam, Mr. Eno served as CEO of Preview Medical, Inc., a diagnostic equipment company focused on AI-driven cancer diagnostics. His past roles also include Senior Vice President of Marketing for HeartFlow, Inc., and senior marketing and sales leadership positions at OptiMedica (acquired by Abbott), NeoGuide Systems (acquired by Intuitive), and Avantec Vascular (acquired by Goodman Co. Ltd).
Timothy Cruickshank, Chief Financial Officer
Timothy Cruickshank was appointed Chief Financial Officer of HeartBeam in September 2024. He possesses over 15 years of experience in public companies, focusing on scaling businesses that leverage disruptive technologies. Prior to joining HeartBeam, Mr. Cruickshank served as the CFO of ImpediMed, where he was instrumental in transforming the company's business model from a traditional medical device company to a high-margin Software-as-a-Service (SaaS) platform through the introduction of the SOZO® Digital Health Platform. He served as a financial executive at ImpediMed since 2008 and as CFO from October 2019 through March 2024.
Branislav Vajdic, PhD, President and Founder
Dr. Branislav Vajdic is the Founder of HeartBeam, Inc., established in 2015. He served as CEO of HeartBeam until October 2024, when he transitioned to the role of President to focus on advancing the company's vector-based technology and AI applications. Dr. Vajdic brings over 30 years of experience in technology development and senior management. Before founding HeartBeam, from 2007 to 2010, he was the CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices sector. From 1984 to 2007, he worked at Intel, where he was a co-inventor of Flash memory and led engineering groups for Pentium 1 through Pentium 4 designs.
Bryan Humbarger, Chief Commercial Officer
Bryan Humbarger joined HeartBeam in January 2026 as Chief Commercial Officer, bringing over 25 years of experience in commercializing novel medical technologies. Prior to HeartBeam, he was the Chief Commercial Officer at Proprio, a venture-backed surgical guidance company, where he led go-to-market strategy and market development. His experience also includes leadership positions at Eko Health, AliveCor, and HeartFlow. Additionally, Mr. Humbarger co-founded Ventru, an early-stage neurosurgical device company.
Ken Nelson, Partner, Medtech Advantage Fund and Board Member
Ken Nelson is a 20-year executive and innovator in digital health, medical devices, and remote patient monitoring. He currently serves as a partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator, a global medtech and digital health startup accelerator. This role indicates his involvement with private equity-backed ventures. Mr. Nelson also holds positions as Chairman of the Board for CardiaCare and is an active board member for several other cardiac digital health and medtech startups. His previous commercial leadership roles include BioTelemetry (VP Sales), iRhythm (VP Sales & Marketing), and Bardy Diagnostics (Chief Commercial Officer), and he was Head of Digital Health, Diagnostics, and Monitoring for Biotronik.
AI Analysis | Feedback
Key Business Risks for HeartBeam (BEAT)
The following are key risks to HeartBeam's business:
- Regulatory Approvals and Reimbursement Challenges: As a medical technology company offering diagnostic devices and software, HeartBeam faces significant risks related to obtaining and maintaining necessary regulatory approvals (e.g., FDA clearance) for its products. Failure to secure or sustain these approvals would prevent the company from commercializing its solutions. Furthermore, widespread adoption and revenue generation are heavily dependent on securing adequate reimbursement policies from government and private insurance payers for its remote cardiac monitoring and diagnostic services. Uncertainty or unfavorable decisions regarding reimbursement could severely impact the company's financial viability and market penetration.
- Market Adoption and Competition: HeartBeam's success hinges on the adoption of its credit card-sized electrocardiogram machine and cloud-based diagnostic software system by healthcare providers and patients for remote patient monitoring. There is inherent risk in convincing a skeptical medical community and general public to integrate new technology into existing care pathways. The company also operates in a competitive landscape with established medical device companies and other telehealth providers, some of whom may have greater resources, existing market share, or more comprehensive offerings. Slow adoption rates or intense competition could limit market penetration and growth.
- Data Security and Privacy: HeartBeam's business model involves collecting, storing, and transmitting sensitive patient health information through its cloud-based diagnostic software system. This exposes the company to substantial risks related to data security breaches, cyberattacks, and non-compliance with data privacy regulations (e.g., HIPAA). Any security incident could lead to significant financial penalties, reputational damage, loss of patient and physician trust, and potential legal liabilities, severely impacting the business.
AI Analysis | Feedback
The increasing capability and widespread adoption of multi-purpose consumer wearables, such as smartwatches from major technology companies (e.g., Apple, Google, Samsung), that integrate FDA-cleared cardiac monitoring features (like ECG). As these devices become more sophisticated in their medical-grade capabilities and achieve deeper integration into formal healthcare remote patient monitoring workflows, they pose a significant emerging threat by offering a more comprehensive, convenient, and often already-owned alternative to dedicated, single-function medical devices for cardiac monitoring.
AI Analysis | Feedback
HeartBeam (NASDAQ: BEAT) operates in several significant addressable markets related to cardiac disease detection and monitoring outside healthcare facilities. For its telemedicine solutions, which include remote detection and monitoring of cardiac disease, and diagnostic data for care management of patients with cardiovascular disease, HeartBeam addresses the following markets:- The global remote cardiac monitoring market was estimated at USD 3.80 billion in 2024 and is projected to reach approximately USD 10.66 billion by 2034, growing at a CAGR of 10.87% from 2025 to 2034.
- The U.S. remote cardiac monitoring market size was estimated at USD 1.22 billion in 2024 and is predicted to be worth around USD 3.46 billion by 2034. North America held the largest market share in the remote cardiac monitoring market in 2024.
- The global telecardiology market was valued at USD 23.60 billion in 2024 and is anticipated to reach USD 112.92 billion by 2033, growing at a CAGR of 19% from 2024 to 2033. North America dominated the telecardiology market with an 11.68% share in 2025.
- The global cardiovascular digital solutions market was valued at USD 8.5 billion in 2024 and is projected to reach an estimated USD 22.5 billion by 2030, growing at a robust CAGR of 13.5%. This market was valued at $84.4 billion in 2022 and is estimated to reach $154.1 billion by 2032, growing at a CAGR of 6.2% from 2023 to 2032. North America had the highest cardiovascular digital solutions market share in 2022. Remote Patient Monitoring (RPM) is expected to be the largest application segment, comprising around 50% of the market share in 2024.
- The global mobile ECG devices market size was valued at USD 2.9 billion in 2024 and is expected to reach USD 7.51 billion by 2032, growing at a CAGR of 11.17% from 2025 to 2032. Another estimate places the global mobile ECG devices market at USD 4.53 billion in 2025, projected to grow to USD 10.87 billion by 2034.
- The U.S. mobile ECG devices market was valued at USD 1.20 billion in 2024 and is expected to reach USD 2.77 billion by 2032. North America dominated the global mobile ECG devices market in 2022, accounting for 48.5% of the total market share.
- The global portable ECG monitoring devices market was valued at USD 2.483 billion in 2024 and is projected to grow to USD 5.306 billion by 2032, exhibiting a CAGR of 11.6% during the forecast period.
AI Analysis | Feedback
HeartBeam, Inc. (BEAT) is positioned for future revenue growth over the next 2-3 years through several key drivers, primarily stemming from the commercialization and expansion of its innovative cardiac monitoring technologies.
- Commercial Launch and Market Adoption of FDA-Cleared Products: A significant driver of revenue growth is the ongoing commercialization and market adoption of HeartBeam's recently FDA-cleared technologies. The company received 510(k) clearance for its HeartBeam System (3D ECG technology for arrhythmia assessment) in December 2024 and for its 12-lead ECG synthesis software in December 2025. HeartBeam has initiated a limited market release, initially targeting concierge and preventive cardiology groups, and has secured its first commercial partnership with ClearCardio™.
- Expansion to New Market Segments and Partnerships: Beyond its initial limited launch, expanding into broader market segments and forging additional commercial partnerships are expected to fuel revenue growth. The company's strategy aligns with the burgeoning mobile ECG devices market, which is projected to grow significantly, suggesting ample opportunity for market penetration with its remote patient monitoring solutions.
- Future FDA Indication Expansion for Heart Attack Detection: A crucial long-term growth driver is the potential expansion of FDA indications to include heart attack detection. HeartBeam has commenced patient enrollment for the ALIGN ACS European pilot study, which aims to compare its ECG technology with conventional 12-lead ECGs for detecting heart attacks in emergency room settings, with results anticipated by the end of 2026. Successful expansion of this indication would significantly broaden the addressable market for HeartBeam's technology.
- Introduction of Extended-Wear 12-Lead ECG Patch: The development and subsequent commercialization of an extended-wear 12-lead ECG patch represent another potential revenue stream. HeartBeam has completed the first working prototype of this device, indicating an expansion of its product portfolio designed to cater to continuous cardiac monitoring needs.
- Leveraging AI-Powered ECG Algorithms through Strategic Collaborations: HeartBeam's strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the development of next-generation AI-ECG algorithms using its 3D signal technology is expected to enhance the capabilities and market appeal of its offerings. The integration of advanced artificial intelligence could provide superior diagnostic insights, differentiate its products, and attract a larger customer base, contributing to revenue growth.
AI Analysis | Feedback
Share Issuance
- HeartBeam filed a shelf registration statement on Form S-3 in February 2026, authorizing the offer and sale of up to $100,000,000 of various securities over time, with approximately $78,844,988 of previously registered securities remaining unsold.
- In February 2025, the company raised a net of $10.25 million through a public offering and an additional $0.49 million via its At-the-Market (ATM) program.
- HeartBeam completed a sale of Common Stock in May 2023, generating gross proceeds of $26.5 million.
Capital Expenditures
- HeartBeam invested $82,000 in capital expenditures in Q3 2025, primarily for funding long-term assets and infrastructure.
- Over the last 12 months leading up to Q3 2025, capital expenditures amounted to $184,000.
- Net cash used in investing activities was approximately $600,000 for the full year 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| HeartBeam Stock Surges 388%, With A 9-Day Winning Spree | 12/17/2025 | |
| HeartBeam Stock Surges 273%, With A 8-Day Winning Spree | 12/16/2025 | |
| HeartBeam Stock 7-Day Winning Spree: Stock Climbs 227% | 12/13/2025 | |
| HeartBeam Stock Surges 201%, With A 6-Day Winning Spree | 12/12/2025 | |
| 5-Day Rally Sends HeartBeam Stock Up 120% | 12/11/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BEAT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
| 12312018 | BEAT | BioTelemetry [DELISTED] | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | -17.8% | -22.5% | -37.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 37.69 |
| Mkt Cap | 4.5 |
| Rev LTM | 1,228 |
| Op Inc LTM | -7 |
| FCF LTM | 30 |
| FCF 3Y Avg | 48 |
| CFO LTM | 121 |
| CFO 3Y Avg | 76 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.5% |
| Rev Chg 3Y Avg | 5.7% |
| Rev Chg Q | 2.3% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Mgn LTM | 0.4% |
| Op Mgn 3Y Avg | 4.4% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 10.7% |
| CFO/Rev 3Y Avg | 14.1% |
| FCF/Rev LTM | 5.9% |
| FCF/Rev 3Y Avg | 9.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.5 |
| P/S | 1.3 |
| P/EBIT | 1.7 |
| P/E | 2.5 |
| P/CFO | 8.0 |
| Total Yield | -1.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.0% |
| D/E | 0.2 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -17.7% |
| 3M Rtn | -26.3% |
| 6M Rtn | -21.9% |
| 12M Rtn | -13.5% |
| 3Y Rtn | -25.5% |
| 1M Excs Rtn | -12.3% |
| 3M Excs Rtn | -17.4% |
| 6M Excs Rtn | -17.3% |
| 12M Excs Rtn | -29.2% |
| 3Y Excs Rtn | -87.0% |
Price Behavior
Price Behavior
| Market Price | $1.14 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/11/2021 | |
| Distance from 52W High | -66.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.46 | $1.53 |
| DMA Trend | down | down |
| Distance from DMA | -21.8% | -25.7% |
| 3M | 1YR | |
| Volatility | 84.3% | 149.8% |
| Downside Capture | 3.08 | 1.39 |
| Upside Capture | 214.69 | 106.43 |
| Correlation (SPY) | 32.2% | 13.7% |
BEAT Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.72 | 2.57 | 4.02 | 1.29 | 1.01 | 1.33 |
| Up Beta | 2.60 | 1.52 | 2.39 | -3.30 | 0.20 | 0.57 |
| Down Beta | 2.61 | -0.43 | 1.79 | 2.00 | 1.44 | 1.73 |
| Up Capture | 464% | 231% | 1107% | 172% | 99% | 156% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 15 | 26 | 52 | 102 | 318 |
| Down Capture | 402% | 488% | 223% | 139% | 126% | 111% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 23 | 32 | 63 | 130 | 388 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BEAT | |
|---|---|---|---|---|
| BEAT | -41.8% | 149.3% | 0.28 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 8.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 13.6% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 9.6% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 12.1% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 4.5% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BEAT | |
|---|---|---|---|---|
| BEAT | -24.8% | 118.8% | 0.23 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 12.8% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 15.1% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 3.6% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 3.4% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 7.9% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 10.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BEAT | |
|---|---|---|---|---|
| BEAT | -13.3% | 118.8% | 0.23 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 12.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 15.1% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 3.6% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 3.4% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 7.9% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 10.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/20/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.